GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Asset Turnover

RPTX (Repare Therapeutics) Asset Turnover : 0.00 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Repare Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Repare Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $191.45 Mil. Therefore, Repare Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Repare Therapeutics's annualized ROE % for the quarter that ended in Dec. 2024 was -70.34%. It is also linked to ROA % through Du Pont Formula. Repare Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -59.90%.


Repare Therapeutics Asset Turnover Historical Data

The historical data trend for Repare Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics Asset Turnover Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial - 0.02 0.36 0.17 0.25

Repare Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.20 - - -

Competitive Comparison of Repare Therapeutics's Asset Turnover

For the Biotechnology subindustry, Repare Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repare Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Asset Turnover falls into.



Repare Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Repare Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=53.477/( (253.901+176.506)/ 2 )
=53.477/215.2035
=0.25

Repare Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (206.389+176.506)/ 2 )
=0/191.4475
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Repare Therapeutics  (NAS:RPTX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Repare Therapeutics's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-114.684/163.045
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-114.684 / 0)*(0 / 191.4475)*(191.4475/ 163.045)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1742
=ROA %*Equity Multiplier
=-59.90 %*1.1742
=-70.34 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Repare Therapeutics's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-114.684/191.4475
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-114.684 / 0)*(0 / 191.4475)
=Net Margin %*Asset Turnover
= %*0
=-59.90 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Repare Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Repare Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
Executives
Maria Koehler officer: EVP, Chief Medical Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Michael Zinda officer: EVP, Chief Science Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Steve Forte officer: EVP, Chief Financial Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Lloyd Mitchell Segal officer: President and CEO 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage I, L.p. 10 percent owner ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Repare Therapeutics Headlines

From GuruFocus